ARTES 20th Year Anniversary – a short overview
In 2002 at May 10th Michael Piontek founded ARTES as a one-man operation executing and taking care of two license deals…
In 2002 at May 10th Michael Piontek founded ARTES as a one-man operation executing and taking care of two license deals…
ARTES Biotechnology, the German-based biotech company specializing in process development for recombinant vaccines, ente…
ARTES Biotechnology and Burnet Institute recently published data on the efficient production of malaria vaccine candidat…
ARTES Biotechnology announces the acquisition of the unique SplitCore technology developed by scientists at the Universi…
Under the titel: “ERA-Net EuroTransBio-8: PLURIVAX, development of a virus-like-particle (VLP) based vaccine platform an…
The French R&D tax credit CIR gives French companies the ability to claim tax relief on 30% on all generated costs outso…
ARTES Biotechnology specialized in microbial process development and technology transfer for pharmaceutical industry is…
ARTES Biotechnology and Burnet Institute announce they have joined forces to develop a novel, effective vaccine to preve…
ARTES Biotechnology, specialized in recombinant protein production, process and vaccine development from microbial expre…
B3C newswire / -[/b] ARTES Biotechnology, InstrAction and Q-Biologicals establish a three-party consortium for vaccine d…